Industry News
Biotechnology Industry News

UPDATE: Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 program
UPDATE: Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 program klahucik Fri, 01/28/2022 - 14:37
Charles River Labs deals with SAMDI Tech to boost discovery business
Charles River Labs deals with SAMDI Tech to boost discovery business aarmstrong Fri, 01/28/2022 - 12:58
Yet another delay at Amryt as EMA calls in experts to inform review of rare disease drug
Yet another delay at Amryt as EMA calls in experts to inform review of rare disease drug ntaylor Fri, 01/28/2022 - 08:20
Homology scratches cash itch with manufacturing deal, bagging $130M to fund gene therapy trials
Homology scratches cash itch with manufacturing deal, bagging $130M to fund gene therapy trials ntaylor Fri, 01/28/2022 - 06:31
Taysha mulls tweaks to gene therapy trial after subject dies
Taysha mulls tweaks to gene therapy trial after subject dies ntaylor Thu, 01/27/2022 - 08:45
Neck and neck with Pfizer, Moderna gives first dose of omicron-specific booster in phase 2 trial
Neck and neck with Pfizer, Moderna gives first dose of omicron-specific booster in phase 2 trial ntaylor Thu, 01/27/2022 - 07:23
9-year J&J science chief Stoffels to steer Galapagos’ rebound as CEO
9-year J&J science chief Stoffels to steer Galapagos' rebound as CEO klahucik Wed, 01/26/2022 - 16:35
Septerna emerges with $100M to spark ‘second golden age’ of prolific drug target GPCR with pioneer as co-founder
Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder klahucik Wed, 01/26/2022 - 15:34
Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit
Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit ntaylor Wed, 01/26/2022 - 06:49
Gilead’s $4.9B oncology bet hit with partial clinical hold, forcing pause of pivotal trials and raising doubts about CD47
Gilead's $4.9B oncology bet hit with partial clinical hold, forcing pause of pivotal trials and raising doubts about CD47 ntaylor Wed, 01/26/2022 - 05:49
Gilead tags along again to support cell therapy biotech Kyverna in $85M fundraising
Gilead tags along again to support cell therapy biotech Kyverna in $85M fundraising aarmstrong Tue, 01/25/2022 - 14:00
Pfizer, BioNTech launch trial for potential omicron-busting vaccine
Pfizer, BioNTech launch trial for potential omicron-busting vaccine aarmstrong Tue, 01/25/2022 - 09:29
Sierra’s bet on Gilead castoff pays off, teeing up FDA filing for rival to Incyte-Novartis cancer drug
Sierra's bet on Gilead castoff pays off, teeing up FDA filing for rival to Incyte-Novartis cancer drug ntaylor Tue, 01/25/2022 - 08:10
AstraZeneca success torpedoes PCI’s pivotal plan, crushing stock
AstraZeneca success torpedoes PCI's pivotal plan, crushing stock ntaylor Tue, 01/25/2022 - 06:23
89bio, trying to rise from ashes of NASH failures, posts gains in disease severity, cardiovascular health in small data set
89bio, trying to rise from ashes of NASH failures, posts gains in disease severity, cardiovascular health in small data set aarmstrong Mon, 01/24/2022 - 14:51
New clinical trial organization launches with promise to conduct randomized trials at fraction of the cost
New clinical trial organization launches with promise to conduct randomized trials at fraction of the cost aarmstrong Mon, 01/24/2022 - 10:36
1b, or not 1b: FDA hits Viking with clinical hold over mix-up in phase of rare disease trial
1b, or not 1b: FDA hits Viking with clinical hold over mix-up in phase of rare disease trial ntaylor Mon, 01/24/2022 - 08:26
MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year
MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year ntaylor Mon, 01/24/2022 - 07:13
New research on tau’s role in neurodegenerative diseases like Alzheimer’s could inform new treatments
New research on tau's role in neurodegenerative diseases like Alzheimer's could inform new treatments klahucik Fri, 01/21/2022 - 13:51
Alnylam touts data replication for next-generation Onpattro in ATTR trial but analysts pour some cold water
Alnylam touts data replication for next-generation Onpattro in ATTR trial but analysts pour some cold water aarmstrong Fri, 01/21/2022 - 10:40

